A Phase 2/3 interventional study of CA4P and paclitaxel in Anaplastic Thyroid Cancer, sponsored by Mateon Therapeutics. Terminated at 41 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-06-09.
Sponsored by Mateon Therapeutics · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies in Thyroid Carcinoma, Anaplastic with a site in United States — 5 open to participants now, 14 under way, none of them phase 3. Thyroid Carcinoma, Anaplastic · United States.
Among the 50 studies in Thyroid Carcinoma, Anaplastic with a site in United States, this one is the 8th largest by enrollment of the 47 interventional ones that give a count, is the only one that started in 2007, is the only one in phase 2/3, and was the 14th registered.
87 studies on the registry are indexed under Thyroid Carcinoma, Anaplastic; 18 are open to participants now.
Browse Thyroid Carcinoma, Anaplastic studies →5 of the 50 studies in Thyroid Carcinoma, Anaplastic with a site in United States are open now. Recruiting first, the newest first:
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
UNC Lineberger Comprehensive Cancer Center · Sites in United States
Ages 18+
Fore Biotherapeutics · Sites in United States, Australia, Canada and 9 more countries
Ages 8+
Northwestern University · Sites in United States
Ages 18+
Washington University School of Medicine · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 14 Thyroid Carcinoma, Anaplastic studies recruiting now, 14 (100%) set no upper age limit and none (0%) stop at 75 or younger; 3 take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 36 · Phase 3 1
First in 1997; this study’s year is marked. 1 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 80 is above the median of 30 across 71 interventional studies indexed under Thyroid Carcinoma, Anaplastic.
Median enrollment 26 across the 47 interventional studies, 1,000 across the 1 observational. Of the 31 that completed or were terminated, 20 (65%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 50 have an industry lead sponsor. The 10 most frequent:
Mateon Therapeutics is the lead sponsor of 14 studies on the registry; none are open to participants now.
Mateon Therapeutics has 2 studies filed under Thyroid Carcinoma, Anaplastic — fewer than ten, so there is no comparison to draw.
6 of the studies in Thyroid Carcinoma, Anaplastic with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03449108M.D. Anderson Cancer CenterLN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas | 2027-04-30 |
| NCT04238624Memorial Sloan Kettering Cancer CenterStudy of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer | 2027-06-20 |
| NCT03181100M.D. Anderson Cancer CenterAtezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer | 2027-07-31 |
| NCT04171622M.D. Anderson Cancer CenterLenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer | 2027-08-31 |
| NCT03085056Memorial Sloan Kettering Cancer CenterTrametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer | 2027-09 |
Add all 6 to your calendar (.ics) → With an account.
Among the 50 studies in Thyroid Carcinoma, Anaplastic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to determine the safety and efficacy of combretastatin combined with paclitaxel and carboplatin in the treatment of anaplastic thyroid cancer (ATC).
Anaplastic thyroid carcinoma (ATC) is a high-grade neoplasm, characterized by an aggressive clinical course with brief survival, and refractoriness to currently available local and systemic modalities of treatment. There is no standard therapy for ATC, and no randomized comparative trials have been known to be conducted in this disease. One potential strategy is to combine the anti-tumor activity of the vascular disrupting agent combretastatin with conventional cytotoxic agents. This study will compare the overall survival of ATC patients treated with the triplet combination of combretastatin, paclitaxel, and carboplatin compared with the doublet treatment of paclitaxel and carboplatin.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Six 21-day cycles: CA4P (60 mg/m2 on Days 1, 8, 15), carboplatin (AUC 6) + paclitaxel (200 mg/m2) on Day 2
Drug: CA4P
Six 21-day cycles of Carboplatin (AUC 6) + paclitaxel (200 mg/m2) given on Day 1
Drug: paclitaxel · Drug: carboplatin
CA4P 60mg/m squared for Days 1, 8, 15 for 6 cycles
Also known as: combretastatin, fosbretabulin, Zybrestat
200mg/m squared on Day 1
Also known as: Taxol, Paxene
6 AUC on Day 1 following paclitaxel
Also known as: Paraplatin
Overall Survival
Time frame: From randomization to date last known alive
To Determine Progression Free Survival
Time frame: from randomization through end of study visit
To Determine Percentage of 1 Year Survival
Time frame: from randomization through end of study visit
Study truncated from 180 to 80 subjects. Subjects were enrolled from August 2007 through March 2010 at 40 worldwide, academic and local-regional clinical sites.
| Milestone | Arm 1, Active: CA4P + Carboplatin + Paclitaxel | Arm 2, Control: Carboplatin + Paclitaxel |
|---|---|---|
| Started | 55 | 25 |
| Completed | 18 | 7 |
| Not completed | 37 | 18 |
| Withdrew: Disease progression | 12 | 5 |
| Withdrew: Adverse event | 12 | 5 |
| Withdrew: Withdrawal by subject | 3 | 3 |
| Withdrew: Physician decision | 4 | 2 |
| Withdrew: Other | 6 | 3 |
| Milestone | Arm 1, Active: CA4P + Carboplatin + Paclitaxel | Arm 2, Control: Carboplatin + Paclitaxel |
|---|---|---|
| Started | 16 | 0 |
| Completed | 2 | 0 |
| Not completed | 14 | 0 |
| Withdrew: Progressive disease | 14 | 0 |
| months | Arm 1, Active: CA4P + Carboplatin + Paclitaxel | Arm 2, Comparator: Carboplatin + Paclitaxel |
|---|---|---|
| Overall Survival | 5.2 (3.1 to 9.0) | 4.0 (2.8 to 6.2) |
Results for this outcome have not been posted.
| percentage of participants | Arm 1, Active: CA4P + Carboplatin + Paclitaxel | Arm 2, Control: Carboplatin + Paclitaxel |
|---|---|---|
| To Determine Percentage of 1 Year Survival | 26 | 9 |
Collected over Adverse event data was collected over 2 years, 6 months. All serious adverse events were reported, regardless of relatedness. Adverse events occurring at a frequency of >/= 5% in either arm are reported, regardless of relatedness.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm 1, Active: CA4P + Carboplatin + Paclitaxel | — | 21/51 (41.2%) | 50/51 (98%) |
| Arm 2, Comparator: Carboplatin + Paclitaxel | — | 5/24 (20.8%) | 24/24 (100%) |
| Event | Arm 1, Active: CA4P + Carboplatin + Paclitaxel | Arm 2, Comparator: Carboplatin + Paclitaxel |
|---|---|---|
| BronchitisInfections and infestations | 5/51 | 2/24 |
| AnemiaBlood and lymphatic system disorders | 1/51 | 2/24 |
| DyspneaRespiratory, thoracic and mediastinal disorders | 4/51 | 1/24 |
| Febrile NeutropeniaBlood and lymphatic system disorders | 3/51 | 0/24 |
| HyponatremiaMetabolism and nutrition disorders | 0/51 | 1/24 |
| Hypoxic encephalopathyNervous system disorders | 0/51 | 1/24 |
| NeutropeniaBlood and lymphatic system disorders | 2/51 | 1/24 |
| PneumoniaRespiratory, thoracic and mediastinal disorders | 2/51 | 1/24 |
| Respiratory tract infectionInfections and infestations | 0/51 | 1/24 |
| Sinus tachycardiaCardiac disorders | 0/51 | 1/24 |
| Event | Arm 1, Active: CA4P + Carboplatin + Paclitaxel | Arm 2, Comparator: Carboplatin + Paclitaxel |
|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 30/51 | 7/24 |
| AnemiaBlood and lymphatic system disorders | 20/51 | 12/24 |
| LeukopeniaBlood and lymphatic system disorders | 21/51 | 2/24 |
| FatigueGeneral disorders | 18/51 | 7/24 |
| HypertensionVascular disorders | 18/51 | 1/24 |
| AlopeciaSkin and subcutaneous tissue disorders | 16/51 | 3/24 |
| DiarrheaGastrointestinal disorders | 15/51 | 4/24 |
| DyspeaRespiratory, thoracic and mediastinal disorders | 15/51 | 4/24 |
| DysphagiaGastrointestinal disorders | 15/51 | 1/24 |
| NauseaGastrointestinal disorders | 15/51 | 5/24 |
| Age, Categorical(Participants) | Arm 1, Active: CA4P + Carboplatin + Paclitaxel | Arm 2, Control: Carboplatin + Paclitaxel | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 29 | 14 | 43 |
| >=65 years | 26 | 11 | 37 |
| Age, Continuous(years) | Arm 1, Active: CA4P + Carboplatin + Paclitaxel | Arm 2, Control: Carboplatin + Paclitaxel | Total |
|---|---|---|---|
| Mean | 61.5 ± 10.72 | 61.2 ± 10.54 | 61.4 ± 10.60 |
| Sex: Female, Male(Participants) | Arm 1, Active: CA4P + Carboplatin + Paclitaxel | Arm 2, Control: Carboplatin + Paclitaxel | Total |
|---|---|---|---|
| Female | 25 | 18 | 43 |
| Male | 30 | 7 | 37 |
| Region of Enrollment(participants) | Arm 1, Active: CA4P + Carboplatin + Paclitaxel | Arm 2, Control: Carboplatin + Paclitaxel | Total |
|---|---|---|---|
| Belarus | 1 | 1 | 2 |
| United States | 20 | 5 | 25 |
| Poland | 5 | 1 | 6 |
| Ukraine | 1 | 1 | 2 |
| Romania | 1 | 0 | 1 |
| Russian Federation | 2 | 1 | 3 |
| Bulgaria | 3 | 0 | 3 |
| Israel | 2 | 1 | 3 |
| Italy | 13 | 8 | 21 |
| United Kingdom | 2 | 1 | 3 |
| India | 5 | 6 | 11 |
The record gives a start of Aug 2007, a primary completion of Oct 2011 and a completion of Nov 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2014, 2 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fosbretabulin tromethamine
Thyroid Carcinoma, Anaplastic →
Mateon Therapeutics